Immutep Limited

Immutep Limited is a clinical-stage biotechnology company headquartered in Sydney, Australia, with operations also in Germany, France, and the United States. The company is a global leader and pioneer in the development of novel immunotherapies for cancer and autoimmune diseases, specifically focusing on therapeutics related to Lymphocyte Activation Gene-3 (LAG-3). Its mission is to leverage immunotherapy to develop safe, innovative treatment options for patients and to maximize shareholder value through disciplined and accurate research.

Immutep's diversified product portfolio harnesses LAG-3's ability to stimulate or suppress the immune response. The lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3Ig fusion protein designed as an antigen-presenting cell (APC) activator for various cancer treatments. Other key candidates include IMP761, a LAG-3 agonist antibody for autoimmune diseases, and IMP731, a depleting LAG-3 antibody for autoimmune conditions, which has been licensed to GlaxoSmithKline. Additionally, LAG525, an antagonist antibody targeting LAG-3 for cancer treatment, is out-licensed to Novartis.

In March 2026, Immutep discontinued its Phase III TACTI-004 trial in first-line non-small cell lung cancer (NSCLC) following a futility analysis, which led to a significant stock decline. Despite this setback, other efti programs are ongoing, including encouraging data from INSIGHT-003 in lung cancer, the EFTISARC-NEO soft tissue sarcoma trial meeting its primary objective, and continued follow-up for AIPAC-003 in metastatic breast cancer. The Phase I study for IMP761 in autoimmune diseases has shown favorable safety data and is progressing. Efti also received FDA orphan drug designation for soft tissue sarcoma in April 2026. Marc Voigt serves as the CEO, and Dr. Frédéric Triebel, the discoverer of LAG-3, is the Chief Scientific and Medical Officer. The company reported a cash position of A$110.6 million as of March 31, 2026, with an expected cash runway into the first half of calendar year 2028.

Latest updates

Immutep Discontinues Lung Cancer Trial, Faces $10M Payment

Event summary

  • Immutep discontinued the TACTI-004 Phase III trial for eftilagimod alfa in 1L NSCLC following a recommendation from the Independent Data Monitoring Committee (IDMC) based on interim futility analysis involving ~170 patients.
  • The trial showed underperformance of the efti combination arm compared to the placebo arm, a result unexpected given prior data like INSIGHT-003.
  • Immutep is conducting a root cause analysis, potentially extending into Q3 CY2026, and faces a $10 million payment obligation to Dr. Reddy’s.
  • The company has A$110.6 million in cash and cash equivalents, expected to last into H1 CY2028, but will implement cost reduction measures including headcount reduction.
  • IMP761, an autoimmune disease candidate, is progressing to a multiple ascending dose phase, with data expected at EULAR 2026.

The big picture

The discontinuation of TACTI-004 represents a significant setback for Immutep, highlighting the inherent risks in clinical-stage drug development, particularly in immuno-oncology where response rates can be highly variable and difficult to predict. The unexpected futility signal raises questions about the efficacy of eftilagimod alfa in combination therapies and could impact investor confidence in the broader LAG-3 immunotherapy field. The $10 million payment to Dr. Reddy's will pressure Immutep’s already stretched financials.

What we're watching

Clinical Strategy
How Immutep’s root cause analysis of the TACTI-004 failure will impact the broader eftilagimod alfa development program and its overall immunotherapy strategy.
Financial Stability
Whether Immutep can sustain its cash runway into H1 CY2028 given the $10 million payment to Dr. Reddy’s and the costs associated with the trial wind-down and cost reduction measures.
Partner Dynamics
The extent to which Dr. Reddy’s continues to support Immutep’s eftilagimod alfa program, particularly given the disappointing TACTI-004 results and the associated financial obligation.

Immutep Slides Below Nasdaq Minimum Bid Price, Enters Compliance Period

Event summary

  • Immutep has received a deficiency notice from Nasdaq for failing to maintain a minimum bid price of US$1.00 per share.
  • The non-compliance is based on the closing bid price over the 30 business days ending April 24, 2026.
  • Immutep has 180 calendar days, until October 26, 2026, to regain compliance.
  • The company remains listed on the Australian Securities Exchange (ASX).

The big picture

This deficiency notice highlights the challenges faced by smaller-cap biotech companies in maintaining Nasdaq listing requirements, particularly during periods of market volatility or clinical trial uncertainty. A sustained bid price below $1.00 can trigger delisting concerns and limit access to capital markets, potentially hindering Immutep's ability to fund its immunotherapy development pipeline. The company's ability to navigate this compliance period will be a key indicator of its long-term viability.

What we're watching

Shareholder Response
The market's reaction to this notice will likely influence Immutep's ability to regain compliance, potentially impacting investor confidence and share price.
Capital Raising
Management may be pressured to consider equity or debt financing to bolster the share price, which could dilute existing shareholders or introduce restrictive covenants.
Clinical Progress
The speed and success of Immutep's clinical trials will be critical; positive data could drive investor interest and help restore the share price to above the $1.00 threshold.
CID: 3599